Diabetes News and Research

Latest Diabetes News and Research

Entest BioMedical and Quantum Advisors sign Letter of Intent

Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

3 Nov 2009

Medco Health Solutions reports third-quarter total net revenues of $14.8 billion

Medco Health Solutions, Inc. today reported record third-quarter 2009 GAAP diluted earnings per share of $0.69, up 19.0 percent compared to $0.58 for the third quarter of 2008.

3 Nov 2009

40% of African-Americans with diabetes delay a visit to a podiatrist: APMA

New national survey results show that nearly 40 percent of African-Americans with diabetes delay a visit to a podiatrist -- a critical member of a diabetes management team -- because they cannot afford the necessary medical care, according to the American Podiatric Medical Association (APMA).

3 Nov 2009

PCNA launches "Family at Heart" educational campaign

Recent research indicates that despite decades of progress, fewer Americans are now considered "low risk" for heart disease compared to years past. Adding fuel to the fire, a new study is making headlines with the alarming statistic that 7 in 10 obese teens already have at least one risk factor for heart disease.

3 Nov 2009

Roche Applied Science to launch the NimbleGen CGX arrays in Europe and Japan

Roche Applied Science will announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.

3 Nov 2009

$Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study$

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

Aggressively managing patients at risk for osteoporosis could reduce the hip fracture rate in the United States by 25 percent, according to a Kaiser Permanente study published in the November issue of the Journal of Bone & Joint Surgery. The first step must be a more active role by orthopedic surgeons in osteoporosis disease management, researchers say.

3 Nov 2009

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

Decreased physical activity may have little to do with the recent spike in obesity rates among U.S. adolescents, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

FDA updates Byetta prescribing information following reports of kidney problems

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

3 Nov 2009

Mortal combination of health problems that can double the risk of heart attack identified

Researchers at the University of Warwick have identified a particular combination of health problems that can double the risk of heart attack and cause a three-fold increase in the risk of mortality.

3 Nov 2009

NIA funds national Testosterone Trial, Penn Medicine to lead

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions.

2 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

Update from Novo Nordisk regarding its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

From Novo Nordisk 2 Nov 2009

ISB and Complete Genomics embark on the largest complete human genome disease association study

The Institute for Systems Biology (ISB) and Complete Genomics Inc. announced today that they are embarking on a large-scale human genome sequencing study of Huntington’s disease (HD). ISB has engaged Complete Genomics to sequence 100 genomes, the majority of which will be used to investigate this disease, with samples from affected individuals, family members, and matched controls to study modifiers of disease presentation and progression.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Dietary cholesterol is not a primary factor for coronary heart disease

Contrary to the established view, current data suggest that dietary cholesterol is not a primary factor of or causes heart disease - with the possible exception of the genetic forms of familial hypercholesterolemias. For instance, recent clinical trials evaluating the effect of cholesterol-lowering drugs on the development of chronic heart failure, diabetes and stroke have yielded disappointing results.

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

Diabetes News and Research

Latest Diabetes News and Research

Entest BioMedical and Quantum Advisors sign Letter of Intent

Medco Health Solutions reports third-quarter total net revenues of $14.8 billion

40% of African-Americans with diabetes delay a visit to a podiatrist: APMA

PCNA launches "Family at Heart" educational campaign

Roche Applied Science to launch the NimbleGen CGX arrays in Europe and Japan

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA updates Byetta prescribing information following reports of kidney problems

Mortal combination of health problems that can double the risk of heart attack identified

NIA funds national Testosterone Trial, Penn Medicine to lead

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Update from Novo Nordisk regarding its share repurchase programme

ISB and Complete Genomics embark on the largest complete human genome disease association study

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Dietary cholesterol is not a primary factor for coronary heart disease

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

American Diabetes Association launches "Stop Diabetes" campaign

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Diabetes News and Research

Latest Diabetes News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in